PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Insights
  • Our team
  • Join us

CJEU clarifies jurisdiction rules for European patent enforcement: BSH Hausgeräte vs. Electrolux AB

  • Sector: Uncategorized
  • 1st March 2025
 

Earlier this week the CJEU provided its ruling in the highly anticipated case of BSH Hausgeräte v. Electrolux (Case C-339/22, February 2025). The case addressed longstanding questions about the jurisdiction of European courts when patent invalidity is raised as a defence in an infringement case. The CJEU found that national courts maintain jurisdiction over infringement claims against defendants domiciled in their territory, even when invalidity of foreign patents is raised. The case follows a recent UPC case that tackled similar questions relating to the jurisdiction of the UPC to hear cases relating to UK patent infringement (UPC_CFI_355/2023). 

BSH sued Electrolux (a Swedish company) in Sweden. BSH alleged that Electrolux infringed its EP1434512 (relating to vacuum cleaners) which was validated in certain EU states and Turkey. BSH requested an injunction and damages for infringement in all these countries. In response, Electrolux argued that the patents were invalid and that the court had no jurisdiction, claiming that Article 24(4) of the Brussels Regulation meant that if invalidity was raised, the court would lose jurisdiction over the infringement case. 

Article 4(1) Brussels I Regulation (Regulation 1215/2012) states that “persons domiciled in a Member State shall, whatever their nationality, be sued in the courts of that Member State“. 

Article 24 Brussels I Regulation (Regulation 1215/2012) states that: “The following courts of a Member State shall have exclusive jurisdiction, regardless of the domicile of the parties […] (4) in proceedings concerned with the registration or validity of patents […] irrespective of whether the issue is raised by way of an action or as a defence, the courts of the Member State in which the deposit or registration has been applied for“. 

The Swedish court of appeal referred the following questions to the CJEU: 

1. Does a court that has jurisdiction for patent infringement under Article 4(1) of the Regulation lose its jurisdiction if the validity of the patent is contested? Or does the court only have jurisdiction to decide on validity?

2. Is it relevant whether national law requires a separate invalidity action?

3. Does Article 24(4) of the Regulation also apply to courts of third countries (here: Turkey)?

The CJEU ruled in BSH’s favour, finding that Article 24(4) should be strictly interpreted as an exception to the general rule of Article 4(1). The CJEU particularly found that whilst national courts cannot rule on the validity of foreign patents, they can continue hearing infringement claims, with the option to stay proceedings if there’s a reasonable possibility the patent might be invalidated in its country of registration. The CJEU concluded that under Article 4(1), the court in which the defendant is domiciled remains competent to decide on patent infringement, even if the patent was granted in another European state and even if the validity of the patent is contested. At the same time, the CJEU confirmed the exclusive jurisdiction of the courts of the patent-granting state to decide on the validity of the patent. 

Therefore, according to the CJEU decision, EU courts (including the UPC) can look at the question of validity of European patents in non-EU countries to determine infringement issues. However, the EU court’s decision will not affect the existence or content of the patent in that third country (para. 74).

Related insights...

Referral on description amendments finally confirmed (G1/25 – “Hydroponics”)

  • 29th July 2025
At last, the wait is over. After years of conflicting case law and mounting frustration for practitioners, the Enlarged Board of Appeal is set to rule on the controversial issue of description amendments in G1/25. But will the decision actually bring clarity ?

G 1/24 in the spotlight: Description definitions do not override clear claim language (T 1999/23)

  • 24th July 2025
The latest decision from the EPO to apply the landmark decision in G1/24 on claim interpretation finds that description definitions should not override clear claim lanaguge.

The problem with product-by-process patents (T 1065/23)

  • 18th July 2025
Inventions may be defined in a patent as product, a process, or a product defined by the process that it is made. The choice of patent claim format you choose to define the invention can be highly influential to validity and enforcement later on.

First interpretation of G 1/24 (the description must always be consulted) (T 1561/23)

  • 14th July 2025
Did G1/24 really change everything about claim interpretation, or does it simply formalize what Boards of Appeal were already doing case-by-case?”

Pitfalls of cell therapy manufacturing IP – A case study (T 0868/23)

  • 8th July 2025
In cell therapy the industry mantra is that the product is the process. However, this case illustrates that the best patent protection for a cell therapy is derived from the product. 

Non-reproducible commercial products are prior art (G1/23)

  • 7th July 2025
Is your product prior art if you disclose it before you file your patent, but without disclosing how it is made or what it is made from? The EBA answers “yes”.

The morality (and patentability) of inventions derived by immoral means (T 2510/18)

  • 25th June 2025
Should patents be granted for inventions born from unethical practices, even if they offer significant societal benefits?

How to read a biotech patent

  • 23rd June 2025
Learn how to quickly search for and extract key information from biotech patent documents.

EBA decides G1/24 on claim interpretation: The description should always be consulted

  • 19th June 2025
Understanding how patent claims are interpreted is crucial, and a recent EPO decision, G 1/24, provides new guidance: always consult the patent’s full description and drawings, not just the claims themselves.

Is it time for patent offices to enter the bioinformatic age?

  • 13th June 2025
In a world in which incalculable amounts of sophisticated sequence data is freely available, are the clunky processes necessary to input patent sequence data really fit-for-purpose?
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Subscribe

Contact Us